Laddar populära aktier...
Redeye estimates an 85% probability of the Neonode side settling against Samsung in mid-2025, which would give an estimated USD31 per share ...
Redeye states that today’s ruling about a reversed decision from last year’s marksman hearing increases Neonode’s chances of a successful ou...
Redeye states that while the Q2 report held few positive surprises, all eyes are now (once again) on the lawsuit.
Redeye thinks the financial development in Q2 was weak, with the only positive surprise (product sales) being of one-time character.
Redeye comments on last week’s positive decision for patent ‘879.
Redeye makes a few comments following last week's hearing in Aequitas' patent lawsuit, which involves appeals from all infringing parties, i...
Redeye notes that Neonode's strategic shift has resulted in a first license agreement for it's touch sensor module technology with YesAR, wh...
Redeye in this note comments Neonode’s Q1’24 and the last major news around the Aequitas lawsuit.
Redeye notes that Neonode's CEO is leaving the company effective immediately, and therefore provides a brief comment in this research note.
Redeye updates its research following Neonode's year-end report.
Redeye in this note provides a brief initial comment on the report.
Redeye in this note briefly comments on the latest happenings in the 879 patent litigation process.
Redeye has a positive first impression of Neonode's press release of today, where the company announced that it is phasing out the Products ...
Redeye provides the following initial take on Neonode's automotive contract announced earlier today.
Redeye states that following a long streak of dissatisfactory sales, Neonode is now clearly re-directing its focus towards the Automotive in...
Redeye notes that the Neonode Q3'23 report was weaker than expected.
Redeye states that the chances of Neonode winning or settling its lawsuit against Apple and Samsung have significantly been reduced.
Redeye states that the Q2 report was on the weaker side, once again, especially from the products business.
Redeye comments on yesterday’s ruling in the lawsuit - in which the judge ruled that the whole patent 879 is invalid.
Redeye thinks the meaning of the verdict from the Markman hearing is unclear.
Redeye states that the Q1 report was weak, but that the Automotive segment is progressing well and indicates a promise of high license reven...
Redeye states that the Q1 report was weak. However, as Redeye has stated many times before, it currently views the lawsuit against Samsung a...
Redeye updates its view on Neonode following a strong Q4 report and an updated view on the lawsuit.
Redeye states that the Q4 report was very strong - from both segments but with particular emphasis on product sales.
Redeye updates its view on the lawsuit with a new schedule and an updated view on the number of units involved and the royalty fee per unit.
Redeye provides an updated walkthrough of its assumptions in the lawsuit against Apple, Samsung, and Alphabet.
Redeye states that Neonode’s patent 879 is judged not to be unpatentable – implying a crucial win for the Neonode side against Samsung, Appl...
The final documentation in patent litigation 879 against Apple and Samsung is now public.
Redeye states that the first part of the IPR process for patent 879 has favoured Neonode.
Redeye states that Q3 revenues are still not satisfactory but that it’s good that the burn rate is kept to a minimum through a lower cost ba...
Redeye thinks that the Neonode side made a strong oral hearing last night for patent 879.
Redeye states that Q2 came in below estimates and that much needs to happen on the growth side to regain investors’ trust.
Redeye states that the Q2 report was weaker than expected, with external factors still hampering the business.
Redeye states that the initial decision of IPR was negative for Neonode.
Redeye thinks that the new evidence from the patent founder was strong and improves Neonode’s chances of winning the lawsuit against Apple a...
Redeye states that Q1 came in below estimates and assesses that acceleration of product sales will likely be slower than previously expected...
Redeye states that the Q1 report was weaker than expected.
Redeye states that last night’s oral hearing involved reinstated hope in surviving the ‘993 IPR through an earlier conception date.
Redeye states that Q4 came in below estimates and that the rapid acceleration is likely pushed forward.
Redeye states that the Q4 report came in below estimates, but that License Sales was strong.
Redeye states that even though Q2 was below our estimates, the investment case remains intact as we know that ramping up sales will take tim...
Redeye states that the Q2 report came in below our expectations, especially on sales from HMI Products.
